US blood companies to use NAT (nucleic acid testing) for HIV/HCV, says FDA:
This article was originally published in Clinica
Executive Summary
The US FDA has gently warned blood manufacturers that they need to begin incorporating nucleic acid testing technology (NAT) to screen for HIV-1 and Hepatitis C. In a draft guidance document issued last week, the agency said that manufacturers should implement NAT testing for the two viruses within six months of final guidance being issued. The notice was published in the Federal Register on April 9. Comments are due by July 8 so the agency can prepare the final document, the FDA said.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.